Literature DB >> 3261154

In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases.

L Turner-Stokes1, G Cambridge, T Corcoran, J S Oxford, M L Snaith.   

Abstract

Reduced in vitro anti-influenza antibody response by peripheral blood mononuclear cells (PBMs) after vaccination was confirmed in a group of 28 patients with systemic lupus erythematosus (SLE), and also in 16 patients with some other autoimmune syndromes. This group of patients with SLE had higher serum anti-DNA binding, but there was no evidence of increased autoantibody production after vaccination, nor any clinical or laboratory evidence of flares in disease activity that are sometimes seen to follow intercurrent infection. Although a reduced in vitro antibody response may, to some extent, reflect redistribution of antibody producing cells, there appears to be more generalised impairment of the immune response in these patients, which cannot be accounted for by steroid/immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261154      PMCID: PMC1003565          DOI: 10.1136/ard.47.7.532

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

1.  Immunoregulatory aberrations in systemic lupus erythematosus.

Authors:  A S Fauci; A D Steinberg; B F Haynes; G Whalen
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

2.  Impaired immunoglobulin synthesis by peripheral blood lymphocytes in systemic lupus erythematosus.

Authors:  K M Nies; J S Louie
Journal:  Arthritis Rheum       Date:  1978 Jan-Feb

3.  Defective in vitro antibody production to Varicella zoster and other virus antigens in patients with Hodgkin's disease.

Authors:  R L Souhami; J Babbage; A Sigfusson
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

4.  Histocompatibility requirements for T cell help in specific in vitro antibody responses to influenza virus by human blood lymphocytes.

Authors:  R E Callard; C M Smith
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

5.  Specific in vitro antibody response to influenza virus by human blood lymphocytes.

Authors:  R E Callard
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Specific allogeneic help by T lymphocytes from patients with systemic lupus erythematosus.

Authors:  M K Hari Kumar; R A Knight; M L Snaith
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

8.  Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram-negative infections.

Authors:  D A Isenberg; P Maddison; G Swana; R P Skinner; M Swana; M Jones; I Addison; C Dudeney; S Shall; A el Roiey
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

  8 in total
  7 in total

1.  Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.

Authors:  A Holvast; A Huckriede; J Wilschut; G Horst; J J C De Vries; C A Benne; C G M Kallenberg; M Bijl
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

2.  Heptavax-B in pediatric dialysis patients: effect of systemic lupus erythematosus. Chesapeake Pediatric Nephrology Study Group.

Authors:  M M Moxey-Mims; K Preston; B Fivush; F McCurdy
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

Review 3.  Immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  L Turner-Stokes; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-07       Impact factor: 19.103

4.  Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.

Authors:  I Fomin; D Caspi; V Levy; N Varsano; Y Shalev; D Paran; D Levartovsky; I Litinsky; I Kaufman; I Wigler; E Mendelson; O Elkayam
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

Review 5.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

Review 6.  The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease.

Authors:  Yu Bin Seo; Su Jin Moon; Chan Hong Jeon; Joon Young Song; Yoon Kyoung Sung; Su Jin Jeong; Ki Tae Kwon; Eu Suk Kim; Jae Hoon Kim; Hyoun Ah Kim; Dong Jin Park; Sung Hoon Park; Jin Kyun Park; Joong Kyong Ahn; Ji Seon Oh; Jae Won Yun; Joo Hyun Lee; Hee Young Lee; Min Joo Choi; Won Suk Choi; Young Hwa Choi; Jung Hyun Choi; Jung Yeon Heo; Hee Jin Cheong; Shin Seok Lee
Journal:  Infect Chemother       Date:  2020-06

7.  Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Authors:  Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.